Ozone therapy: an overview of pharmacodynamics, current research, and clinical utility

Background

Ozone (O3) has been used as a complementary therapy for a wide range of conditions for decades, but its reactive and inherently unstable molecular structure has made many in mainstream medicine sceptical of how - or whether - it could work safely in the body. A research team based largely at Stony Brook University School of Medicine set out to pull together the scattered laboratory and clinical evidence on ozone therapy into a single, structured overview: how it is thought to act on tissue, what routes and doses are used, what the contraindications are, and where the clinical evidence for benefit is strongest.

Study design

This was a narrative literature review rather than a clinical trial or laboratory experiment - the authors did not enrol patients or run new experiments. Instead, they synthesised previously published laboratory and clinical research on ozone therapy, organising it around several themes: mechanisms of action, routes and concentrations of administration, contraindications, and ozone's disinfectant activity against various microorganisms. They then reviewed the clinical evidence for ozone use across a number of pathology groups, including cardiovascular disease, gastrointestinal disorders, genitourinary conditions, central nervous system disorders, head and neck conditions, musculoskeletal disorders, subcutaneous tissue conditions, and peripheral vascular disease.

Findings

According to the studies reviewed, ozone's reactive chemistry allows it to interact with lipids in a way that produces a moderate, short-lived increase in oxidative stress. Rather than being purely damaging, this controlled stress response appears to trigger the body's own antioxidant defences, improve local blood flow and oxygen delivery to tissue, and modulate immune activity. Mapping this mechanism against the clinical literature, the authors report that the strongest and most consistent evidence for ozone's benefit sits in diabetic foot ulcers, ischaemic wounds, and peripheral vascular disease - areas where ozone therapy is already most widely used in practice. Evidence for benefit in the other pathology categories reviewed was described as present but more variable in strength and quality. The review also summarises ozone's disinfectant properties against a range of bacteria, viruses, and fungi.

What the authors concluded

The authors concluded that ozone therapy has a plausible biological mechanism and a genuine, evidence-supported role in certain conditions - particularly vascular and wound-related pathologies - but that the overall evidence base remains uneven across the many uses they surveyed. They called for further, more rigorous studies before ozone therapy could be considered a mainstream, first-line treatment option in medicine generally.

Limitations of this study

As a narrative review rather than a systematic review or meta-analysis, this paper did not follow a pre-registered search protocol, apply formal inclusion/exclusion criteria, or carry out a structured risk-of-bias assessment of the studies it drew on. Its conclusions are only as strong as the individual laboratory and clinical studies cited, many of which vary in size, design, and quality, and no pooled statistical analysis was performed to quantify the overall strength of evidence. Mechanistic claims about oxidative stress and antioxidant response are drawn substantially from laboratory and preclinical work rather than uniformly from controlled human trials. Publication bias - where positive results are more likely to be published than null ones - cannot be ruled out across the wider literature the review summarises.